Interleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical  benefit and harm

dc.contributor.authorParrish, A.
dc.contributor.authorGray, A. 
dc.contributor.authorKredo, T. 
dc.contributor.authorMaartens, G. 
dc.contributor.authorReubenson, G.
dc.contributor.authorCohen, K.
dc.contributor.authorDe Waal, R.
dc.contributor.authorBlockman, M.
dc.contributor.authorNel, J.
dc.contributor.authorRees, H.
dc.contributor.department Cochrane South Africa, South  African Medical Research Councilen_US
dc.date.accessioned2020-07-20T09:08:58Z
dc.date.available2020-07-20T09:08:58Z
dc.date.epub2020-04-15
dc.date.issued2020-04-15
dc.identifier.urihttps://infospace.mrc.ac.za/handle/11288/595270
dc.language.isoenen_US
dc.publisherSouth African National Department of Healthen_US
dc.research.unitSouth African Cochrane Centreen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.titleInterleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical  benefit and harmen_US
dc.typeOtheren_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Parris A_2020_Iinterleukin-6 inhibitor.pdf
Size:
241.3 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: